<DOC>
	<DOCNO>NCT02139839</DOCNO>
	<brief_summary>The purpose study determine whether L. rhamnosus GR-1 L. reuteri RC-14 delivered via capsule vagina post-menopausal woman three day course treatment restore maintain lactobacilli-dominated microbiota . Exploratory analysis microbial ecology , human microarrays multiplex immunological assessment include characterize potential effect .</brief_summary>
	<brief_title>Exploratory Study Evaluate Effects Probiotics L. Rhamnosus GR-1 L. Reuteri RC-14</brief_title>
	<detailed_description />
	<mesh_term>Vaginosis , Bacterial</mesh_term>
	<criteria>Willing able read , understand , sign Informed Consent Form ( ICF ) ; Postmenopausal females age 40 80 year old ( subject menstrual period last 12 month ) ; Currently mutually monogamous sexual relationship sexually active ; Agree sexually abstinent 72 hour prior study visit . Also , agree refrain intercourse 48 hour treatment administration ; Agree abstain use intravaginal product ( e.g . gel , foam , lubricant , douche , etc . ) throughout study period , time screen Day 47 ; Willing capable follow study instruction ; Good general health . Use vaginal lubricant , product apply vaginally within three month prior Visit 1and throughout duration study participation ; A history currently undergo immunosuppressive drug therapy , chemotherapy , radiation therapy ; A medical condition might compromise immune system function ( cancer , leucopenia , HIVpositive , organ transplant ) ; Antibiotics and/or antifungal medication use within last four ( 4 ) week ; Oral probiotic supplement use within 3 month prior Visit 1 throughout duration study ; Significant change diet course study base selfreport ; Induced menopause due surgical medical intervention , bilateral oophorectomy , hysterectomy , chemotherapy radiation treatment ; Currently undergo local systemic estrogen therapy willing alter therapy course study ; A Nugent Score 0 3 great 6 ; History drug alcohol abuse ; Currently diagnose treat genital infection urinary tract infection ; Individuals sexually transmit disease ( selfreported detect Principal Investigator ) ; At enrollment , social medical condition , psychiatric illness , opinion Investigator , would preclude provision inform consent , make participation study unsafe , complicate interpretation study outcome data , otherwise interfere achieve study objective ; Participation clinical trial involve investigational product/device within past three month ; subject schedule participate another clinical study concurrently ; Known intolerance allergy L. rhamnosus GR1® L. reuteri RC14® product excipients .</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>